414 related articles for article (PubMed ID: 26424649)
1. Primary Immunodeficiencies Associated with EBV Disease.
Cohen JI
Curr Top Microbiol Immunol; 2015; 390(Pt 1):241-65. PubMed ID: 26424649
[TBL] [Abstract][Full Text] [Related]
2. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
3. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
Latour S; Winter S
Front Immunol; 2018; 9():1103. PubMed ID: 29942301
[TBL] [Abstract][Full Text] [Related]
4. When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.
Sacco KA; Notarangelo LD; Delmonte OM
Clin Microbiol Infect; 2023 Apr; 29(4):457-462. PubMed ID: 36209991
[TBL] [Abstract][Full Text] [Related]
5. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
6. Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.
Cohen JI; Dropulic L; Hsu AP; Zerbe CS; Krogmann T; Dowdell K; Hornung RL; Lovell J; Hardy N; Hickstein D; Cowen EW; Calvo KR; Pittaluga S; Holland SM
Clin Infect Dis; 2016 Jul; 63(1):41-7. PubMed ID: 27169477
[TBL] [Abstract][Full Text] [Related]
7. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
Cohen JI
Front Immunol; 2018; 9():237. PubMed ID: 29599765
[TBL] [Abstract][Full Text] [Related]
8. The immunology of Epstein-Barr virus-induced disease.
Taylor GS; Long HM; Brooks JM; Rickinson AB; Hislop AD
Annu Rev Immunol; 2015; 33():787-821. PubMed ID: 25706097
[TBL] [Abstract][Full Text] [Related]
9. EBV in T-/NK-Cell Tumorigenesis.
Kimura H
Adv Exp Med Biol; 2018; 1045():459-475. PubMed ID: 29896680
[TBL] [Abstract][Full Text] [Related]
10. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
11. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.
Heslop HE
Hematology Am Soc Hematol Educ Program; 2005; ():260-6. PubMed ID: 16304390
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival.
Liang JH; Wang C; Yiu SPT; Zhao B; Guo R; Gewurz BE
mBio; 2021 Aug; 12(4):e0153021. PubMed ID: 34281398
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity in Epstein Barr virus specific immune control.
Münz C
Curr Opin Virol; 2021 Feb; 46():1-8. PubMed ID: 32771660
[TBL] [Abstract][Full Text] [Related]
14. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
15. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
16. An Update on XMEN Disease.
Ravell JC; Chauvin SD; He T; Lenardo M
J Clin Immunol; 2020 Jul; 40(5):671-681. PubMed ID: 32451662
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults.
Suzuki K; Ohshima K; Karube K; Suzumiya J; Ohga S; Ishihara S; Tamura K; Kikuchi M
Int J Oncol; 2004 May; 24(5):1165-74. PubMed ID: 15067338
[TBL] [Abstract][Full Text] [Related]
18. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
Worth AJ; Houldcroft CJ; Booth C
Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
[TBL] [Abstract][Full Text] [Related]
19. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection.
Kasahara Y; Yachie A; Takei K; Kanegane C; Okada K; Ohta K; Seki H; Igarashi N; Maruhashi K; Katayama K; Katoh E; Terao G; Sakiyama Y; Koizumi S
Blood; 2001 Sep; 98(6):1882-8. PubMed ID: 11535525
[TBL] [Abstract][Full Text] [Related]
20. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
Front Pediatr; 2019; 7():183. PubMed ID: 31231620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
